Dr. Armand is a distinguished European oncologist, with more than 40 years of experience in cancer research and clinical oncology, focusing on the identification of novel mechanisms of oncogenesis and early drug development.
A senior consultant for Gustave Roussy (GR) Phase 1 unit (DITEP) and Cancer Campus Grand Paris, Dr. Armand was CEO of Institut Claudius Regaud in Toulouse, CEO of the Hospital GR3, head of the Department of Medical oncology at GR2 and CMO of GR&D, Department of Innovation and Development at GR. As the founder of DITEP, he ran the first human phase I trial in the world at IGR for classical cytotoxics, Topo2 inhibitors and more recently targeted therapies, Sutent, Sorafenib, and Temsirolimus.
Dr. Armand is an active member of the International Cancer community. He served as President of the European Society for Medical Oncology (ESMO), as a member of International Boards of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO) and as a Medical Director of the Federation of European Cancer Societies (FECS).
Throughout his career, he has received numerous awards including: an ESMO Award as “the European oncologist of the year”, Targeted Anticancer Therapy (TAT) honorary award in recognition of his contribution to new drug discovery in cancer, the European Lung cancer award in Athens and he is a Chevalier of French Legion d’honneur.
He has (co)authored over 300 medical and scientific peer-reviewed articles and he is/was a member of the Editorial Boards of Annals of Oncology, the European Journal of Cancer, Journal of Clinical Oncology, Investigational New Drugs, Anticancer Research, Clinical Cancer Research, and CISCO Journal.
Dr. Armand has a Degree in Medicine and was awarded Certification in Medical Oncology from the University of Toulouse III and Paris XI.